SAM
RXRX icon

Smartleaf Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Smartleaf Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.48K Buy
874
+297
+51% +$1.15K ﹤0.01% 2902
2025
Q4 		$2.37K Buy
577
+406
+237% +$2.01K ﹤0.01% 2936
2025
Q3 		$839 Buy
+171
New +$898 ﹤0.01% 2778
2025
Q1 		– Sell
-269
Closed -$1.82K – 2979
2024
Q4 		$1.82K Hold
269
– – ﹤0.01% 2553
2024
Q3 		$1.88K Buy
269
+249
+1,245% +$1.78K ﹤0.01% 2492
2024
Q2 		$151 Buy
+20
New +$174 ﹤0.01% 2703

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Smartleaf Asset Management's RXRX Position: Q1 2026 in Review

Smartleaf Asset Management increased its Recursion Pharmaceuticals (RXRX) stake by 51% in Q1 2026, buying an estimated $1.15K and bringing the position to 874 shares worth $2.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2902.

Smartleaf Asset Management first reported a position in RXRX in Q2 2024 and has held it in 6 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Smartleaf Asset Management held 874 shares of Recursion Pharmaceuticals worth $2.48K as of Q1 2026.
  • Smartleaf Asset Management bought 297 Recursion Pharmaceuticals shares in Q1 2026, an estimated $1.15K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2902 holding.
  • Smartleaf Asset Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.